Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
631
archived clinical trials in
Vaccines

A Trial to Assess the Lot Consistency, Safety, Tolerability and Immunogenicity of Bivalent rLP2086 Vaccine When Given to Healthy Subjects Aged ≥10 to <19 Years
A Phase 3, Randomized, Active-controlled, Observer-blinded Trial To Assess The Lot Consistency, Safety, Tolerability, And Immunogenicity Of A Meningococcal Serogroup B Bivalent Rlp2086 Vaccine In Healthy Subjects Aged >/=10 To <19 Years
Status: Enrolling
Updated:  3/13/2015
PEAK Research LLC
mi
from
Upper St. Clair, PA
A Trial to Assess the Lot Consistency, Safety, Tolerability and Immunogenicity of Bivalent rLP2086 Vaccine When Given to Healthy Subjects Aged ≥10 to <19 Years
A Phase 3, Randomized, Active-controlled, Observer-blinded Trial To Assess The Lot Consistency, Safety, Tolerability, And Immunogenicity Of A Meningococcal Serogroup B Bivalent Rlp2086 Vaccine In Healthy Subjects Aged >/=10 To <19 Years
Status: Enrolling
Updated: 3/13/2015
PEAK Research LLC
mi
from
Upper St. Clair, PA
Click here to add this to my saved trials
A Trial to Assess the Lot Consistency, Safety, Tolerability and Immunogenicity of Bivalent rLP2086 Vaccine When Given to Healthy Subjects Aged ≥10 to <19 Years
A Phase 3, Randomized, Active-controlled, Observer-blinded Trial To Assess The Lot Consistency, Safety, Tolerability, And Immunogenicity Of A Meningococcal Serogroup B Bivalent Rlp2086 Vaccine In Healthy Subjects Aged >/=10 To <19 Years
Status: Enrolling
Updated:  3/13/2015
Focus Research Group
mi
from
Hendersonville, TN
A Trial to Assess the Lot Consistency, Safety, Tolerability and Immunogenicity of Bivalent rLP2086 Vaccine When Given to Healthy Subjects Aged ≥10 to <19 Years
A Phase 3, Randomized, Active-controlled, Observer-blinded Trial To Assess The Lot Consistency, Safety, Tolerability, And Immunogenicity Of A Meningococcal Serogroup B Bivalent Rlp2086 Vaccine In Healthy Subjects Aged >/=10 To <19 Years
Status: Enrolling
Updated: 3/13/2015
Focus Research Group
mi
from
Hendersonville, TN
Click here to add this to my saved trials
A Trial to Assess the Lot Consistency, Safety, Tolerability and Immunogenicity of Bivalent rLP2086 Vaccine When Given to Healthy Subjects Aged ≥10 to <19 Years
A Phase 3, Randomized, Active-controlled, Observer-blinded Trial To Assess The Lot Consistency, Safety, Tolerability, And Immunogenicity Of A Meningococcal Serogroup B Bivalent Rlp2086 Vaccine In Healthy Subjects Aged >/=10 To <19 Years
Status: Enrolling
Updated:  3/13/2015
Holston Medical Group, PC
mi
from
Kingsport, TN
A Trial to Assess the Lot Consistency, Safety, Tolerability and Immunogenicity of Bivalent rLP2086 Vaccine When Given to Healthy Subjects Aged ≥10 to <19 Years
A Phase 3, Randomized, Active-controlled, Observer-blinded Trial To Assess The Lot Consistency, Safety, Tolerability, And Immunogenicity Of A Meningococcal Serogroup B Bivalent Rlp2086 Vaccine In Healthy Subjects Aged >/=10 To <19 Years
Status: Enrolling
Updated: 3/13/2015
Holston Medical Group, PC
mi
from
Kingsport, TN
Click here to add this to my saved trials
A Trial to Assess the Lot Consistency, Safety, Tolerability and Immunogenicity of Bivalent rLP2086 Vaccine When Given to Healthy Subjects Aged ≥10 to <19 Years
A Phase 3, Randomized, Active-controlled, Observer-blinded Trial To Assess The Lot Consistency, Safety, Tolerability, And Immunogenicity Of A Meningococcal Serogroup B Bivalent Rlp2086 Vaccine In Healthy Subjects Aged >/=10 To <19 Years
Status: Enrolling
Updated:  3/13/2015
Holston Medical Group Laboratory
mi
from
Kingsport, TN
A Trial to Assess the Lot Consistency, Safety, Tolerability and Immunogenicity of Bivalent rLP2086 Vaccine When Given to Healthy Subjects Aged ≥10 to <19 Years
A Phase 3, Randomized, Active-controlled, Observer-blinded Trial To Assess The Lot Consistency, Safety, Tolerability, And Immunogenicity Of A Meningococcal Serogroup B Bivalent Rlp2086 Vaccine In Healthy Subjects Aged >/=10 To <19 Years
Status: Enrolling
Updated: 3/13/2015
Holston Medical Group Laboratory
mi
from
Kingsport, TN
Click here to add this to my saved trials
A Trial to Assess the Lot Consistency, Safety, Tolerability and Immunogenicity of Bivalent rLP2086 Vaccine When Given to Healthy Subjects Aged ≥10 to <19 Years
A Phase 3, Randomized, Active-controlled, Observer-blinded Trial To Assess The Lot Consistency, Safety, Tolerability, And Immunogenicity Of A Meningococcal Serogroup B Bivalent Rlp2086 Vaccine In Healthy Subjects Aged >/=10 To <19 Years
Status: Enrolling
Updated:  3/13/2015
Cumberland Pediatrics Associates
mi
from
Lebanon, TN
A Trial to Assess the Lot Consistency, Safety, Tolerability and Immunogenicity of Bivalent rLP2086 Vaccine When Given to Healthy Subjects Aged ≥10 to <19 Years
A Phase 3, Randomized, Active-controlled, Observer-blinded Trial To Assess The Lot Consistency, Safety, Tolerability, And Immunogenicity Of A Meningococcal Serogroup B Bivalent Rlp2086 Vaccine In Healthy Subjects Aged >/=10 To <19 Years
Status: Enrolling
Updated: 3/13/2015
Cumberland Pediatrics Associates
mi
from
Lebanon, TN
Click here to add this to my saved trials
A Trial to Assess the Lot Consistency, Safety, Tolerability and Immunogenicity of Bivalent rLP2086 Vaccine When Given to Healthy Subjects Aged ≥10 to <19 Years
A Phase 3, Randomized, Active-controlled, Observer-blinded Trial To Assess The Lot Consistency, Safety, Tolerability, And Immunogenicity Of A Meningococcal Serogroup B Bivalent Rlp2086 Vaccine In Healthy Subjects Aged >/=10 To <19 Years
Status: Enrolling
Updated:  3/13/2015
Pediatric Research of Charlottesville, LLC
mi
from
Charlottesville, VA
A Trial to Assess the Lot Consistency, Safety, Tolerability and Immunogenicity of Bivalent rLP2086 Vaccine When Given to Healthy Subjects Aged ≥10 to <19 Years
A Phase 3, Randomized, Active-controlled, Observer-blinded Trial To Assess The Lot Consistency, Safety, Tolerability, And Immunogenicity Of A Meningococcal Serogroup B Bivalent Rlp2086 Vaccine In Healthy Subjects Aged >/=10 To <19 Years
Status: Enrolling
Updated: 3/13/2015
Pediatric Research of Charlottesville, LLC
mi
from
Charlottesville, VA
Click here to add this to my saved trials
A Trial to Assess the Lot Consistency, Safety, Tolerability and Immunogenicity of Bivalent rLP2086 Vaccine When Given to Healthy Subjects Aged ≥10 to <19 Years
A Phase 3, Randomized, Active-controlled, Observer-blinded Trial To Assess The Lot Consistency, Safety, Tolerability, And Immunogenicity Of A Meningococcal Serogroup B Bivalent Rlp2086 Vaccine In Healthy Subjects Aged >/=10 To <19 Years
Status: Enrolling
Updated:  3/13/2015
Pediatric Research of Charlottesville, LLC
mi
from
Charlottesville, VA
A Trial to Assess the Lot Consistency, Safety, Tolerability and Immunogenicity of Bivalent rLP2086 Vaccine When Given to Healthy Subjects Aged ≥10 to <19 Years
A Phase 3, Randomized, Active-controlled, Observer-blinded Trial To Assess The Lot Consistency, Safety, Tolerability, And Immunogenicity Of A Meningococcal Serogroup B Bivalent Rlp2086 Vaccine In Healthy Subjects Aged >/=10 To <19 Years
Status: Enrolling
Updated: 3/13/2015
Pediatric Research of Charlottesville, LLC
mi
from
Charlottesville, VA
Click here to add this to my saved trials
A Trial to Assess the Lot Consistency, Safety, Tolerability and Immunogenicity of Bivalent rLP2086 Vaccine When Given to Healthy Subjects Aged ≥10 to <19 Years
A Phase 3, Randomized, Active-controlled, Observer-blinded Trial To Assess The Lot Consistency, Safety, Tolerability, And Immunogenicity Of A Meningococcal Serogroup B Bivalent Rlp2086 Vaccine In Healthy Subjects Aged >/=10 To <19 Years
Status: Enrolling
Updated:  3/13/2015
Advanced Pediatrics
mi
from
Vienna, VA
A Trial to Assess the Lot Consistency, Safety, Tolerability and Immunogenicity of Bivalent rLP2086 Vaccine When Given to Healthy Subjects Aged ≥10 to <19 Years
A Phase 3, Randomized, Active-controlled, Observer-blinded Trial To Assess The Lot Consistency, Safety, Tolerability, And Immunogenicity Of A Meningococcal Serogroup B Bivalent Rlp2086 Vaccine In Healthy Subjects Aged >/=10 To <19 Years
Status: Enrolling
Updated: 3/13/2015
Advanced Pediatrics
mi
from
Vienna, VA
Click here to add this to my saved trials
A Trial to Assess the Lot Consistency, Safety, Tolerability and Immunogenicity of Bivalent rLP2086 Vaccine When Given to Healthy Subjects Aged ≥10 to <19 Years
A Phase 3, Randomized, Active-controlled, Observer-blinded Trial To Assess The Lot Consistency, Safety, Tolerability, And Immunogenicity Of A Meningococcal Serogroup B Bivalent Rlp2086 Vaccine In Healthy Subjects Aged >/=10 To <19 Years
Status: Enrolling
Updated:  3/13/2015
The Vancouver Clinic
mi
from
Vancouver, WA
A Trial to Assess the Lot Consistency, Safety, Tolerability and Immunogenicity of Bivalent rLP2086 Vaccine When Given to Healthy Subjects Aged ≥10 to <19 Years
A Phase 3, Randomized, Active-controlled, Observer-blinded Trial To Assess The Lot Consistency, Safety, Tolerability, And Immunogenicity Of A Meningococcal Serogroup B Bivalent Rlp2086 Vaccine In Healthy Subjects Aged >/=10 To <19 Years
Status: Enrolling
Updated: 3/13/2015
The Vancouver Clinic
mi
from
Vancouver, WA
Click here to add this to my saved trials
Transcutaneous Immunization With an Attenuated Listeria Monocytogenes Vector Vaccine
Transcutaneous Immunization With actA/plcB-Deleted Listeria Monocytogenes Expressing Influenza A Nucleoprotein (BMB72) and Cholera Toxin Adjuvant
Status: Enrolling
Updated:  9/30/2015
Massachusetts General Hospital
mi
from
Boston, MA
Transcutaneous Immunization With an Attenuated Listeria Monocytogenes Vector Vaccine
Transcutaneous Immunization With actA/plcB-Deleted Listeria Monocytogenes Expressing Influenza A Nucleoprotein (BMB72) and Cholera Toxin Adjuvant
Status: Enrolling
Updated: 9/30/2015
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Pilot Study of the Rotavirus Vaccine in Infants With Intestinal Failure
Pilot Study of the Safety and Immunogenicity of the Rotavirus Vaccine in Infants With Intestinal Failure
Status: Enrolling
Updated:  11/17/2015
Seattle Children's Hospital
mi
from
Seattle, WA
Pilot Study of the Rotavirus Vaccine in Infants With Intestinal Failure
Pilot Study of the Safety and Immunogenicity of the Rotavirus Vaccine in Infants With Intestinal Failure
Status: Enrolling
Updated: 11/17/2015
Seattle Children's Hospital
mi
from
Seattle, WA
Click here to add this to my saved trials
Safety and Immunogenicity Study of Recombinant Ricin Toxin A-Chain Vaccine (RVEc™)
Phase 1 Escalating, Multiple-Dose Study to Evaluate the Safety and Immunogenicity of Recombinant Ricin Toxin A-Chain 1-33/44-198 (rRTA 1-33/44-198) Vaccine (RVEc™) in Healthy Adults
Status: Enrolling
Updated:  12/30/2015
Department of Clinical Research, U.S. Army Medical Research Institute of Infectious Diseases
mi
from
Fort Detrick, MD
Safety and Immunogenicity Study of Recombinant Ricin Toxin A-Chain Vaccine (RVEc™)
Phase 1 Escalating, Multiple-Dose Study to Evaluate the Safety and Immunogenicity of Recombinant Ricin Toxin A-Chain 1-33/44-198 (rRTA 1-33/44-198) Vaccine (RVEc™) in Healthy Adults
Status: Enrolling
Updated: 12/30/2015
Department of Clinical Research, U.S. Army Medical Research Institute of Infectious Diseases
mi
from
Fort Detrick, MD
Click here to add this to my saved trials
Text Message Vaccine Reminders for Adolescents With Chronic Medical Conditions
Text Message Vaccine Reminders for Adolescents With Chronic Medical Conditions
Status: Enrolling
Updated:  1/26/2016
NewYork-Presbyterian Hospital at Columbia University Medical Center
mi
from
New York, NY
Text Message Vaccine Reminders for Adolescents With Chronic Medical Conditions
Text Message Vaccine Reminders for Adolescents With Chronic Medical Conditions
Status: Enrolling
Updated: 1/26/2016
NewYork-Presbyterian Hospital at Columbia University Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
AZD9150, a STAT3 Antisense Oligonucleotide, in People With Malignant Ascites
A Pilot Study of AZD9150, a STAT3 Antisense Oligonucleotide in Malignant Ascites
Status: Enrolling
Updated:  2/8/2017
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
AZD9150, a STAT3 Antisense Oligonucleotide, in People With Malignant Ascites
A Pilot Study of AZD9150, a STAT3 Antisense Oligonucleotide in Malignant Ascites
Status: Enrolling
Updated: 2/8/2017
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
AFIX to Improve HPV Vaccination
Adolescent AFIX: A Multi-state RCT to Increase Adolescent Vaccination by Facilitating Providers' Adoption of Best Practices
Status: Enrolling
Updated:  2/23/2017
Illinois Department of Public Health
mi
from
Springfield, IL
AFIX to Improve HPV Vaccination
Adolescent AFIX: A Multi-state RCT to Increase Adolescent Vaccination by Facilitating Providers' Adoption of Best Practices
Status: Enrolling
Updated: 2/23/2017
Illinois Department of Public Health
mi
from
Springfield, IL
Click here to add this to my saved trials
AFIX to Improve HPV Vaccination
Adolescent AFIX: A Multi-state RCT to Increase Adolescent Vaccination by Facilitating Providers' Adoption of Best Practices
Status: Enrolling
Updated:  2/23/2017
Michigan Department of Community Health
mi
from
Lansing, MI
AFIX to Improve HPV Vaccination
Adolescent AFIX: A Multi-state RCT to Increase Adolescent Vaccination by Facilitating Providers' Adoption of Best Practices
Status: Enrolling
Updated: 2/23/2017
Michigan Department of Community Health
mi
from
Lansing, MI
Click here to add this to my saved trials
AFIX to Improve HPV Vaccination
Adolescent AFIX: A Multi-state RCT to Increase Adolescent Vaccination by Facilitating Providers' Adoption of Best Practices
Status: Enrolling
Updated:  2/23/2017
Univ of North Carolina
mi
from
Chapel Hill, NC
AFIX to Improve HPV Vaccination
Adolescent AFIX: A Multi-state RCT to Increase Adolescent Vaccination by Facilitating Providers' Adoption of Best Practices
Status: Enrolling
Updated: 2/23/2017
Univ of North Carolina
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
AFIX to Improve HPV Vaccination
Adolescent AFIX: A Multi-state RCT to Increase Adolescent Vaccination by Facilitating Providers' Adoption of Best Practices
Status: Enrolling
Updated:  2/23/2017
Washington State Department of Health
mi
from
Olympia, WA
AFIX to Improve HPV Vaccination
Adolescent AFIX: A Multi-state RCT to Increase Adolescent Vaccination by Facilitating Providers' Adoption of Best Practices
Status: Enrolling
Updated: 2/23/2017
Washington State Department of Health
mi
from
Olympia, WA
Click here to add this to my saved trials
Influenza Vaccine Attitudes, Intent, and Receipt: Pediatric
Influenza Vaccine Attitudes, Intent, and Receipt
Status: Enrolling
Updated:  7/26/2017
Columbia University Medical Center
mi
from
New York, NY
Influenza Vaccine Attitudes, Intent, and Receipt: Pediatric
Influenza Vaccine Attitudes, Intent, and Receipt
Status: Enrolling
Updated: 7/26/2017
Columbia University Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
Influenza Vaccine Randomized Educational Trial: Adult
Status: Enrolling
Updated:  7/26/2017
Columbia University Medical Center
mi
from
New York, NY
Influenza Vaccine Randomized Educational Trial: Adult
Status: Enrolling
Updated: 7/26/2017
Columbia University Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
Special Access Program IMVAMUNE®
A Special Access Program for the Prophylactic Vaccination With IMVAMUNE® for Personnel Working Directly With or in the Vicinity of Replicating Vaccinia Virus
Status: Enrolling
Updated:  3/14/2018
Palo Alto Medical Foundation
mi
from
Palo Alto, CA
Special Access Program IMVAMUNE®
A Special Access Program for the Prophylactic Vaccination With IMVAMUNE® for Personnel Working Directly With or in the Vicinity of Replicating Vaccinia Virus
Status: Enrolling
Updated: 3/14/2018
Palo Alto Medical Foundation
mi
from
Palo Alto, CA
Click here to add this to my saved trials
Study of Meninigococcal Conjugate Vaccine Containing Serogroups A,C,Y,W and X (MCV5) in Healthy Adults
A Phase 1, Double Blind, Randomized, Controlled Study to Evaluate the Safety and Immunogenicity of a New Meningococcal Conjugate Vaccine Containing Serogroups A,C,Y,W and X in Healthy Adults
Status: Enrolling
Updated:  3/19/2018
Center for Vaccine Development
mi
from
Baltimore, MD
Study of Meninigococcal Conjugate Vaccine Containing Serogroups A,C,Y,W and X (MCV5) in Healthy Adults
A Phase 1, Double Blind, Randomized, Controlled Study to Evaluate the Safety and Immunogenicity of a New Meningococcal Conjugate Vaccine Containing Serogroups A,C,Y,W and X in Healthy Adults
Status: Enrolling
Updated: 3/19/2018
Center for Vaccine Development
mi
from
Baltimore, MD
Click here to add this to my saved trials
Study to Evaluate GSK Biologicals' Herpes Zoster Vaccine GSK1437173A in Human Immunodeficiency Virus (HIV)-Infected Subjects
Safety and Immunogenicity of GlaxoSmithKline Biologicals' Herpes Zoster Vaccine 1437173A in Adult HIV-infected Subjects
Status: Enrolling
Updated:  3/30/2018
GSK Investigational Site
mi
from
Long Beach, CA
Study to Evaluate GSK Biologicals' Herpes Zoster Vaccine GSK1437173A in Human Immunodeficiency Virus (HIV)-Infected Subjects
Safety and Immunogenicity of GlaxoSmithKline Biologicals' Herpes Zoster Vaccine 1437173A in Adult HIV-infected Subjects
Status: Enrolling
Updated: 3/30/2018
GSK Investigational Site
mi
from
Long Beach, CA
Click here to add this to my saved trials
Study to Evaluate GSK Biologicals' Herpes Zoster Vaccine GSK1437173A in Human Immunodeficiency Virus (HIV)-Infected Subjects
Safety and Immunogenicity of GlaxoSmithKline Biologicals' Herpes Zoster Vaccine 1437173A in Adult HIV-infected Subjects
Status: Enrolling
Updated:  3/30/2018
GSK Investigational Site
mi
from
San Francisco, CA
Study to Evaluate GSK Biologicals' Herpes Zoster Vaccine GSK1437173A in Human Immunodeficiency Virus (HIV)-Infected Subjects
Safety and Immunogenicity of GlaxoSmithKline Biologicals' Herpes Zoster Vaccine 1437173A in Adult HIV-infected Subjects
Status: Enrolling
Updated: 3/30/2018
GSK Investigational Site
mi
from
San Francisco, CA
Click here to add this to my saved trials
Study to Evaluate GSK Biologicals' Herpes Zoster Vaccine GSK1437173A in Human Immunodeficiency Virus (HIV)-Infected Subjects
Safety and Immunogenicity of GlaxoSmithKline Biologicals' Herpes Zoster Vaccine 1437173A in Adult HIV-infected Subjects
Status: Enrolling
Updated:  3/30/2018
GSK Investigational Site
mi
from
Orlando, FL
Study to Evaluate GSK Biologicals' Herpes Zoster Vaccine GSK1437173A in Human Immunodeficiency Virus (HIV)-Infected Subjects
Safety and Immunogenicity of GlaxoSmithKline Biologicals' Herpes Zoster Vaccine 1437173A in Adult HIV-infected Subjects
Status: Enrolling
Updated: 3/30/2018
GSK Investigational Site
mi
from
Orlando, FL
Click here to add this to my saved trials
Study to Evaluate GSK Biologicals' Herpes Zoster Vaccine GSK1437173A in Human Immunodeficiency Virus (HIV)-Infected Subjects
Safety and Immunogenicity of GlaxoSmithKline Biologicals' Herpes Zoster Vaccine 1437173A in Adult HIV-infected Subjects
Status: Enrolling
Updated:  3/30/2018
GSK Investigational Site
mi
from
Santa Fe, NM
Study to Evaluate GSK Biologicals' Herpes Zoster Vaccine GSK1437173A in Human Immunodeficiency Virus (HIV)-Infected Subjects
Safety and Immunogenicity of GlaxoSmithKline Biologicals' Herpes Zoster Vaccine 1437173A in Adult HIV-infected Subjects
Status: Enrolling
Updated: 3/30/2018
GSK Investigational Site
mi
from
Santa Fe, NM
Click here to add this to my saved trials
Study to Evaluate GSK Biologicals' Herpes Zoster Vaccine GSK1437173A in Human Immunodeficiency Virus (HIV)-Infected Subjects
Safety and Immunogenicity of GlaxoSmithKline Biologicals' Herpes Zoster Vaccine 1437173A in Adult HIV-infected Subjects
Status: Enrolling
Updated:  3/30/2018
GSK Investigational Site
mi
from
Dallas, TX
Study to Evaluate GSK Biologicals' Herpes Zoster Vaccine GSK1437173A in Human Immunodeficiency Virus (HIV)-Infected Subjects
Safety and Immunogenicity of GlaxoSmithKline Biologicals' Herpes Zoster Vaccine 1437173A in Adult HIV-infected Subjects
Status: Enrolling
Updated: 3/30/2018
GSK Investigational Site
mi
from
Dallas, TX
Click here to add this to my saved trials
Study to Evaluate GSK Biologicals' Herpes Zoster Vaccine GSK1437173A in Human Immunodeficiency Virus (HIV)-Infected Subjects
Safety and Immunogenicity of GlaxoSmithKline Biologicals' Herpes Zoster Vaccine 1437173A in Adult HIV-infected Subjects
Status: Enrolling
Updated:  3/30/2018
GSK Investigational Site
mi
from
Hannover,
Study to Evaluate GSK Biologicals' Herpes Zoster Vaccine GSK1437173A in Human Immunodeficiency Virus (HIV)-Infected Subjects
Safety and Immunogenicity of GlaxoSmithKline Biologicals' Herpes Zoster Vaccine 1437173A in Adult HIV-infected Subjects
Status: Enrolling
Updated: 3/30/2018
GSK Investigational Site
mi
from
Hannover,
Click here to add this to my saved trials
Study of Lanreotide in Patients With Metastatic Gastrointestinal Neuroendocrine Tumors Who Are Undergoing Liver-directed Radioembolization With Yttrium-90 Microspheres
A Phase II Study of Lanreotide in Patients With Metastatic Gastrointestinal Neuroendocrine Tumors Undergoing Liver-directed Radioembolization With Yttrium-90 Microspheres (SIR-Spheres®)
Status: Enrolling
Updated:  4/18/2018
Tennessee Oncology, PLLC
mi
from
Nashville, TN
Study of Lanreotide in Patients With Metastatic Gastrointestinal Neuroendocrine Tumors Who Are Undergoing Liver-directed Radioembolization With Yttrium-90 Microspheres
A Phase II Study of Lanreotide in Patients With Metastatic Gastrointestinal Neuroendocrine Tumors Undergoing Liver-directed Radioembolization With Yttrium-90 Microspheres (SIR-Spheres®)
Status: Enrolling
Updated: 4/18/2018
Tennessee Oncology, PLLC
mi
from
Nashville, TN
Click here to add this to my saved trials
Study of Lanreotide in Patients With Metastatic Gastrointestinal Neuroendocrine Tumors Who Are Undergoing Liver-directed Radioembolization With Yttrium-90 Microspheres
A Phase II Study of Lanreotide in Patients With Metastatic Gastrointestinal Neuroendocrine Tumors Undergoing Liver-directed Radioembolization With Yttrium-90 Microspheres (SIR-Spheres®)
Status: Enrolling
Updated:  4/18/2018
Rocky Mountain Cancer Center
mi
from
Denver, CO
Study of Lanreotide in Patients With Metastatic Gastrointestinal Neuroendocrine Tumors Who Are Undergoing Liver-directed Radioembolization With Yttrium-90 Microspheres
A Phase II Study of Lanreotide in Patients With Metastatic Gastrointestinal Neuroendocrine Tumors Undergoing Liver-directed Radioembolization With Yttrium-90 Microspheres (SIR-Spheres®)
Status: Enrolling
Updated: 4/18/2018
Rocky Mountain Cancer Center
mi
from
Denver, CO
Click here to add this to my saved trials
Study of Lanreotide in Patients With Metastatic Gastrointestinal Neuroendocrine Tumors Who Are Undergoing Liver-directed Radioembolization With Yttrium-90 Microspheres
A Phase II Study of Lanreotide in Patients With Metastatic Gastrointestinal Neuroendocrine Tumors Undergoing Liver-directed Radioembolization With Yttrium-90 Microspheres (SIR-Spheres®)
Status: Enrolling
Updated:  4/18/2018
Research Medical Center - HCA Midwest
mi
from
Kansas City, MO
Study of Lanreotide in Patients With Metastatic Gastrointestinal Neuroendocrine Tumors Who Are Undergoing Liver-directed Radioembolization With Yttrium-90 Microspheres
A Phase II Study of Lanreotide in Patients With Metastatic Gastrointestinal Neuroendocrine Tumors Undergoing Liver-directed Radioembolization With Yttrium-90 Microspheres (SIR-Spheres®)
Status: Enrolling
Updated: 4/18/2018
Research Medical Center - HCA Midwest
mi
from
Kansas City, MO
Click here to add this to my saved trials